Federal Food and Nutrition Grants

This funding opportunity supports research initiatives focused on non-communicable diseases related to HIV at institutions in low- and middle-income countries, encouraging innovative projects and collaborations to improve health outcomes for people living with HIV.

This Notice of Funding Opportunity (NOFO) seeks to foster new multi-disciplinary teams to address how HIV Comorbidities and co-infections within the missions of NIDDK and NIAID interact with viral reservoirs, potentially confounding cure strategies aimed at either sustained viral suppression or elimination from the body. These teams will mechanistically interrogate the impact of inflammation, metabolic perturbations, or other pathophysiological processes associated with these comorbidities or co-infections on reservoir dynamics, and/or the interplay of these conditions and co-infections on HIV reservoir biology in ways that are likely to interact with potential cure strategies.

This funding opportunity provides financial support to U.S.-based small businesses that have previously received NIH Phase II or Phase IIB awards, helping them advance their research projects toward commercialization through technical assistance and late-stage development activities.

This grant provides funding for early stage investigators to pursue innovative and high-risk research projects involving human participants, without the need for preliminary data.

This funding opportunity provides financial support to U.S.-based organizations, including universities, nonprofits, and businesses, to help outsourcing facilities produce critical medications that are in short supply and vulnerable to fraud.

The FDA seeks an application to continue to maintain, manage existing consortia groups convened and established by the Critical Path Institute. This is a renewal of the cooperative agreement #5U18FD005320 as part of the Critical Path Initiative. This is in support of Critical Path Initiative introduced in Section 566 of the Federal Food, Drug, and Cosmetic Act. This includes developing innovative, collaborative projects in research, education, and outreach for fostering drug product innovation, enabling the acceleration of development, manufacturing, and translational therapeutics, enhancing safety, efficacy, quality, and performance. This funding opportunity will provide support, depending on availability of FDA funding.

This funding opportunity provides financial support to nonprofit organizations and government agencies to create projects that incentivize SNAP households to purchase and consume healthy fluid milk.

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Office of Medical Policy (OMP) is announcing its intent to accept and consider a single source application for the award of a Cooperative Agreement to the Duke Universitys Duke Clinical Research Institute (DCRI) to support the Clinical Trials Transformation Initiative (CTTI).

The purpose of this funding opportunity announcement (FOA) is to fund innovative research that will strengthen and advance minority health and health equity objectives.Areas of interest include:Proposals that focus on advancing equity in clinical trials by supporting efforts to advance diversity in clinical trials, equitable data efforts by increasing data available on diverse groups including, but not limited to, ethnicity, race, age, disability and geography, and equity of voices by increasing understanding of diverse patient perspectives, preferences, and unmet needs.

The purpose of this funding opportunity is to support the research and development necessary to advance non-invasive (e.g., quantitative tomography-based) technologies, including the development of apparatus, methods, study designs, and methods of data analysis, to characterize and compare the rate and extent to which a topically applied drug becomes available at or near a site of action within the skin in vivo. The expectation is that the funded work will produce an accurate, sensitive and reproducible approach that rapidly measures the (relative) amount of drug present in the skin at a series of depths below the skin surface, which can be utilized to monitor the cutaneous pharmacokinetics (PK) of the drug at selected depths (e.g., in the epidermis) by repeated, serial measurements over time. The intent is to support the eventual development of an alternative, scientifically valid, in vivo cutaneous PK-based approach that can be used to efficiently demonstrate the bioequivalence (BE) of topical products.

This grant provides funding to state agencies that manage the Supplemental Nutrition Assistance Program to implement measures that prevent and detect fraud, particularly related to the misuse of EBT cards.

This funding opportunity supports U.S.-based small businesses in health-related fields to develop innovative technologies, with a focus on projects that can successfully transition to commercialization.

The purpose of the funding opportunity is to expand and advance FDA's Office of Minority Health and Health Equity (OMHHE) work with stakeholders and partners for education, outreach, and public awareness activities on potential risks from skin lightening products containing hydroquinone and/or mercury.Applicants will research and propose innovative and community-based strategies and activities that have the potential to strengthen the science base for education and public health awareness on the use of and potential risks from over-the-counter (OTC) skin lightening products.

Not Available

This funding opportunity provides financial support to institutions with limited NIH funding to enhance their biomedical research capabilities and engage students in scientific inquiry.

This funding opportunity provides financial support for new researchers from diverse backgrounds to conduct small-scale health-related studies, helping them advance towards independent research careers.

This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providing shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P and F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in diverse perspectives, propose unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs that propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for future diabetes researchers. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

The purpose of this cooperative agreement is to contribute to the knowledge base of and development of food safety systems globally due to the increasingly diverse and complex food supply. This cooperative agreement will:1) enhance and broaden FDAs ability to address global food safety and public health issues associated with food,2) provide opportunities to leverage additional resources among WTO member countries, and3) support the FDAs Food Safety Modernization Act (FSMA) and its International Food Safety Capacity Building Plan, which emphasizes the concept of preventing food safety- related problems before they occur and the importance of establishing strong relationships and mutual support among all stakeholders, including multilateral organizations, to improve worldwide food safety. 4) Support global research and capacity building to improve best practices to build effective food safety systems in low- and middle-income countries

FY 2024 WIC General Infrastructure Grants will support WIC State agencies as they continue to modernize the program. Projects will support WIC Infrastructure, including technological, digital, partnership, and/or outreach infrastructure at the State agency level through activities related to outreach, innovation, program modernization, and increased equity in program access through four Tracks/objectives. This RFA includes four application Tracks, each with one Objective. The four Tracks include:1) Updating the State agencys management information system (MIS) and/or electronic benefit transfer (EBT) system to meet new Federal requirements.*Please see notes in the Tracks and Objectives section below for information about State agency model (SAM) user groups. 2) Enhancing the State agencys MIS, EBT system, and/or other technology used to provide WIC benefits and services. These enhancements must provide a better user experience for WIC applicants, participants, and staff and/or to improve longevity, flexibility, program integrity, and/or cost efficiency.3) Increasing WIC awareness among the public through adoption of new WIC branding and/or the conduct of partnership and/or outreach activities.4) Upgrading State and/or local agency technology equipment and/or supplies to improve WIC performance, security, and/or user experience (including by optimizing virtual services). Each Application Submitted Must be for Only One Track. State agencies may apply for one or more of the Tracks outlined above but are limited to one Track per application. Section 4 of the RFA provides details for the application requirements for each Track. For each Track, State agencies may apply either as an individual applicant or as the lead of a multi-State agency collaboration. Any lead of a multi-State agency collaboration will be considered the applicant and the funded recipient (i.e., the grantee). The lead State agency is responsible for completing and submitting all application components and will be the sole recipient of funding for the project; therefore responsible for all funded activities and required reporting.

The "Single Source for Chronic Pancreatitis Clinical Research Consortium (CPCRC) Data Coordinating Center (CPCRC-DCC)" grant aims to fund a Coordination and Data Management Center to continue and complete ongoing research on chronic pancreatitis, diabetes, and pancreatic cancer, focusing on understanding the pathophysiology, risk factors, and potential treatments, while promoting collaboration and data sharing among consortium members.